Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.

Marantz, A; Jovtis, S; Almira, E; Balbiani, L; Castilla, J L; Fein, L; Lewi, D; Pasccon, G; Pinckevicius, R; Uranga, G; Abal, M; Muiño, M; Reale, M; Agusto, S

Marantz, A; Jovtis, S; Almira, E; Balbiani, L; Castilla, J L; Fein, L; Lewi, D; Pasccon, G; Pinckevicius, R; Uranga, G; Abal, M; Muiño, M; Reale, M; Agusto, S.

Affiliation

Marantz A; Grupo de Tumores Gastrointestinales, Hospital Fernandez, Servicio de Oncología, Cerviño 3356 CP 1425, Buenos Aires, Argentina.

Semin Oncol ; 28(3 Suppl 10): 44-9, 2001 Jun.

Article in En | MEDLINE | ID: mdl-11510033

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Pancreatic Neoplasms/drug therapy; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Fluorouracil/administration & dosage; Humans; Leucovorin/administration & dosage; Survival Analysis; Gemcitabine

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Humans Language: En Journal: Semin Oncol Year: 2001 Document type: Article

Search on Google

XML

PubMed Links